23
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Metabolically active CD4+ T cells expressing Glut1 and OX40 preferentially harbor HIV during in vitro infection

      letter

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          High glucose transporter 1 (Glut1) surface expression is associated with increased glycolytic activity in activated CD4+ T cells. Phosphatidylinositide 3‐kinases (PI3K) activation measured by p‐Akt and OX40 is elevated in CD4+Glut1+ T cells from HIV+ subjects. TCR engagement of CD4+Glut1+ T cells from HIV+ subjects demonstrates hyperresponsive PI3K‐mammalian target of rapamycin signaling. High basal Glut1 and OX40 on CD4+ T cells from combination antiretroviral therapy (cART)‐treated HIV+ patients represent a sufficiently metabolically active state permissive for HIV infection in vitro without external stimuli. The majority of CD4+OX40+ T cells express Glut1, thus OX40 rather than Glut1 itself may facilitate HIV infection. Furthermore, infection of CD4+ T cells is limited by p110γ PI3K inhibition. Modulating glucose metabolism may limit cellular activation and prevent residual HIV replication in ‘virologically suppressed’ cART‐treated HIV+ persons.

          Related collections

          Most cited references41

          • Record: found
          • Abstract: found
          • Article: not found

          Fueling immunity: insights into metabolism and lymphocyte function.

          Lymphocytes face major metabolic challenges upon activation. They must meet the bioenergetic and biosynthetic demands of increased cell proliferation and also adapt to changing environmental conditions, in which nutrients and oxygen may be limiting. An emerging theme in immunology is that metabolic reprogramming and lymphocyte activation are intricately linked. However, why T cells adopt specific metabolic programs and the impact that these programs have on T cell function and, ultimately, immunological outcome remain unclear. Research on tumor cell metabolism has provided valuable insight into metabolic pathways important for cell proliferation and the influence of metabolites themselves on signal transduction and epigenetic programming. In this Review, we highlight emerging concepts regarding metabolic reprogramming in proliferating cells and discuss their potential impact on T cell fate and function.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function.

            CD4 T cell activation leads to proliferation and differentiation into effector (Teff) or regulatory (Treg) cells that mediate or control immunity. While each subset prefers distinct glycolytic or oxidative metabolic programs in vitro, requirements and mechanisms that control T cell glucose uptake and metabolism in vivo are uncertain. Despite expression of multiple glucose transporters, Glut1 deficiency selectively impaired metabolism and function of thymocytes and Teff. Resting T cells were normal until activated, when Glut1 deficiency prevented increased glucose uptake and glycolysis, growth, proliferation, and decreased Teff survival and differentiation. Importantly, Glut1 deficiency decreased Teff expansion and the ability to induce inflammatory disease in vivo. Treg cells, in contrast, were enriched in vivo and appeared functionally unaffected and able to suppress Teff, irrespective of Glut1 expression. These data show a selective in vivo requirement for Glut1 in metabolic reprogramming of CD4 T cell activation and Teff expansion and survival. Copyright © 2014 Elsevier Inc. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking.

              Cells require growth factors to support glucose metabolism for survival and growth. It is unclear, however, how noninsulin growth factors may regulate glucose uptake and glucose transporters. We show that the hematopoietic growth factor interleukin (IL)3, maintained the glucose transporter Glut1 on the cell surface and promoted Rab11a-dependent recycling of intracellular Glut1. IL3 required phosphatidylinositol-3 kinase activity to regulate Glut1 trafficking, and activated Akt was sufficient to maintain glucose uptake and surface Glut1 in the absence of IL3. To determine how Akt may regulate Glut1, we analyzed the role of Akt activation of mammalian target of rapamycin (mTOR)/regulatory associated protein of mTOR (RAPTOR) and inhibition of glycogen synthase kinase (GSK)3. Although Akt did not require mTOR/RAPTOR to maintain surface Glut1 levels, inhibition of mTOR/RAPTOR by rapamycin greatly diminished glucose uptake, suggesting Akt-stimulated mTOR/RAPTOR may promote Glut1 transporter activity. In contrast, inhibition of GSK3 did not affect Glut1 internalization but nevertheless maintained surface Glut1 levels in IL3-deprived cells, possibly via enhanced recycling of internalized Glut1. In addition, Akt attenuated Glut1 internalization through a GSK3-independent mechanism. These data demonstrate that intracellular trafficking of Glut1 is a regulated component of growth factor-stimulated glucose uptake and that Akt can promote Glut1 activity and recycling as well as prevent Glut1 internalization.
                Bookmark

                Author and article information

                Contributors
                cpalmer@burnet.edu.au
                Journal
                FEBS Lett
                FEBS Lett
                10.1002/(ISSN)1873-3468
                FEB2
                Febs Letters
                John Wiley and Sons Inc. (Hoboken )
                0014-5793
                1873-3468
                11 October 2017
                October 2017
                : 591
                : 20 ( doiID: 10.1002/feb2.2017.591.issue-20 )
                : 3319-3332
                Affiliations
                [ 1 ] Centre for Biomedical Research Burnet Institute Melbourne Australia
                [ 2 ] Department of Infectious Diseases Monash University Melbourne Australia
                [ 3 ] Department of Microbiology and Immunology University of Melbourne Melbourne Australia
                [ 4 ] CONICET‐Universidad de Buenos Aires Instituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS) Buenos Aires Argentina
                [ 5 ] AIDS Cure Research Collaborative Pittsburgh PA USA
                [ 6 ] Cellular and Molecular Metabolism Laboratory Baker IDI Heart and Diabetes Institute Melbourne Australia
                [ 7 ] Monash Micro Imaging Monash University Melbourne Australia
                [ 8 ] Inflammation and Infection Research School of Medical Sciences University of New South Wales Sydney Australia
                [ 9 ] The Peter Doherty Institute for Infection and Immunity The University of Melbourne and Royal Melbourne Hospital Melbourne Australia
                [ 10 ] Division of Experimental Medicine Department of Medicine University of California, San Francisco San Francisco CA USA
                Author notes
                [*] [* ] Correspondence

                C. S. Palmer, Centre for Biomedical Research, Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia

                Fax: +61 3 9282 2142

                Tel: +61 3 8506 2389

                E‐mail: cpalmer@ 123456burnet.edu.au

                Article
                FEB212843
                10.1002/1873-3468.12843
                5658250
                28892135
                bca798d7-bdba-4477-ab99-94593535f1ee
                © 2017 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies

                This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 21 April 2017
                : 01 September 2017
                : 04 September 2017
                Page count
                Figures: 4, Tables: 1, Pages: 14, Words: 8411
                Funding
                Funded by: NIH
                Award ID: P30 AI027757
                Funded by: Australian Centre for HIV and Hepatitis Virology Research (ACH2)
                Funded by: 2010 Developmental Grant (CNIHR) from the University of Washington Center for AIDS Research (CFAR)
                Funded by: NIH Institutes and Centers (NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIA)
                Funded by: National Health and Medical Research Council of Australia (NHMRC) Principal Research Fellowship
                Categories
                Research Letter
                Research Letters
                Immunology
                Custom metadata
                2.0
                feb212843
                October 2017
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.6 mode:remove_FC converted:22.11.2017

                Molecular biology
                cancer,cd4 t cells,glut1,hiv,immunometabolism,mtor,pi3k
                Molecular biology
                cancer, cd4 t cells, glut1, hiv, immunometabolism, mtor, pi3k

                Comments

                Comment on this article